COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

CLR 131 Combined With Radiation for Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04105543
Recruitment Status : Recruiting
First Posted : September 26, 2019
Last Update Posted : July 28, 2020
National Institute of Dental and Craniofacial Research (NIDCR)
Cellectar Biosciences, Inc.
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
This is a Phase 1 study of the use of an investigational drug that selectively delivers radiation to malignant tumor cells, CLR 131, in combination with external beam radiation therapy (EBRT) in subjects with locoregionally recurrent head and neck cancer. The trial will enroll up to 24 participants who are amenable to retreatment with radiation therapy. Participants who also have distant metastatic disease may be enrolled on this clinical trial, but they must have evaluable disease that will be clinically treated with radiation therapy, as per standard of care. All participants will receive a dosimetry test dose of CLR 131 to establish drug uptake by the tumor and enable Monte Carlo dose estimation based on CLR 131 SPECT/CT imaging evaluation. Participants showing uptake will receive a cumulative tumor dose of 60-70 Gy using personalized dose calculation (via Monte Carlo methods) of CLR 131 combined with external beam radiation.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Drug: CLR 131 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single center, dose escalation and dose expansion study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Therapeutic Combination of CLR 131 With External Beam Radiation in Head and Neck Cancer
Actual Study Start Date : December 20, 2019
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CLR 131 Dose Escalation

Enrollment will start at dose level 1 (first 4 participants). Participants will receive 2 doses of CLR 131 intravenously with the first dose on day 1 followed by the second dose on day 8.

Dose Level -1 (de-escalation dose, if toxicities warrant) = 12.5 mCi/m^2 Dose Level 1 (beginning dose) = 15.6 mCi/m^2 Dose Level 2 (escalation dose) = 18.75 mCi/m^2

Dose escalation will proceed with no limiting toxicities at each level (maximum of 8 participants at each dose level). With maximum tolerated dose confirmed, an expansion phase will proceed.

Drug: CLR 131
CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
Other Name: I-131-CLR1404

Primary Outcome Measures :
  1. Incidence of Adverse Events [ Time Frame: up to 18 weeks ]
    Incidence of adverse events assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Secondary Outcome Measures :
  1. CLR 131 Tumor Uptake via SPECT/CT Imaging [ Time Frame: Up to 8 days ]
    Investigators will use SPECT/CT imaging scans to predict the adsorbed dose of CLR 131 to tumors with the Monte Carlo method.

  2. Median Radiation Treatment Time [ Time Frame: up to 14 weeks ]
  3. Median Number of Dose Delays Due to Toxicity [ Time Frame: up to 14 weeks ]
  4. Overall Response Rate (ORR) [ Time Frame: up to 9 months ]
    ORR defined as the proportion of subjects who experience either a partial response or complete response within 6 months post completion of EBRT as measured by standard of care imaging (e.g. CT, MR, PET-MR).

  5. Change in Swallow Function: DIGEST Scale [ Time Frame: up to 9 months ]
    Swallow function assessed by Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) scale before and after treatment. The DIGEST scale cross references a clinician determined 'safety' grade with an 'efficiency' grade for an overall score between 0-4 where 0 is asymptomatic and 4 is life threatening.

  6. Change in Quality of Life: MDADI Score [ Time Frame: up to 15 months ]
    Quality of life assessed by MD Anderson Dysphagia Inventory score (MDADI) before and after treatment. MDADI is a 36-item self-assessment with global, emotional, functional, and physical sub-scales. Total possible composite score range is 20-100 where 20 is extremely low functioning and 100 is high functioning.

  7. Change in Stimulated Salivary Flow [ Time Frame: up to 9 months ]
    Change in Stimulated Salivary Flow before and after treatment (mL/min).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant must be informed of the investigational nature of the study and must be able to sign a written informed consent.
  • Participants with histologically or cytologically confirmed solid malignancy that has recurred in the head and neck (above the clavicles) region, e.g., participants with recurrent cutaneous squamous cell carcinoma, salivary gland tumors or esthesioneuroblastoma are eligible for this clinical trial.
  • Participants must have undergone previous curative intent therapy, with radiation as a primary or adjuvant therapy.
  • Participants may have distant metastatic disease, as long as the locoregional site of recurrence is deemed eligible for radiation therapy, and treatment of the loco-regional disease is deemed as taking precedence over treatment of the remaining systemic disease.
  • Participants must have at least one evaluable (measurable or non-measurable) recurrent lesion that is amenable to radiation therapy.
  • Participants must demonstrate uptake of CLR 131 via SPECT/CT imaging, as determined by the study radiologist, in the specified site of recurrent/metastatic disease that is to be treated with radiation therapy.
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.
  • Participants must have a life expectancy of at least 6 months.
  • The participant has adequate hematologic function, as evidenced by:

    • an absolute neutrophil count (ANC) ≥ 1500 / µL
    • hemoglobin ≥9 g/dL (5.58 mmol/L)
    • and platelets ≥100,000 / µL

      • If full-dose anticoagulation therapy is used, platelets ≥ 150,000 / µL are required.

        • If participant is on full-dose anticoagulation therapy, the anticoagulation therapy must be reversible, and reversal of the anticoagulation therapy must not be life-threatening, as judged by the investigator.
  • The participant has adequate renal function as defined by:

    • serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or Cockcroft-Gault calculated creatinine clearance >/= 60 ml/min
  • The participant has adequate hepatic function as defined by:

    • total bilirubin ≤ 1.5 mg/dL (25.65 μmol/L)
    • aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 times the ULN
  • Women of childbearing potential (WOCP) have a confirmed negative urine pregnancy test within 24 hours prior to test dose of CLR 131.
  • Participants must use a medically acceptable method of birth control such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence during the study participation and for 6 months after last dose of study drug. Women who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP.
  • Men who are not surgically or medically sterile agree to use an acceptable method of contraception. Male participants with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must abstain from intercourse for three weeks after each CLR 131 dose and agree to use condoms at least 6 months after the last dose of study drug. Total abstinence for the same study period is an acceptable alternative.

Exclusion Criteria:

  • Recurrent tumor recommended for surgical resection based on multidisciplinary Head and Neck Oncology Tumor Board Review
  • Thyroid cancer
  • Known hypersensitivity to iodine
  • Other concurrent severe and/or uncontrolled concomitant medical or psychiatric conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol, per investigator discretion
  • Chemotherapy or major surgery within 4 weeks, or radiotherapy within 2 weeks prior to test dose of CLR 131.
  • Participants with clinically significant adverse events due to agents administered more than 4 weeks prior to test dose of CLR 131 (alopecia and fatigue excluded). Clinical significance to be determined by investigator.
  • The participant is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment.
  • Any ongoing or active infection, including active tuberculosis, hepatitis B or C, or known infection with the human immunodeficiency virus (HIV)
  • Concurrent treatment with any other anti-cancer or investigational agents. Participants cannot be receiving concomitant chemotherapy, radiotherapy, experimental therapy or any other therapy not otherwise outlined by the trial for the purposes of anti-cancer treatment.
  • Participants with a history of or concurrent second primary malignancy (stage III or IV) within 5 years to study enrollment are excluded.
  • Participants with with a history of or concurrent second primary malignancy (stage I or II) that have been treated within 2 years of study enrollment are excluded.
  • Participants that have had total body or hemibody irradiation, or have had prior systemic radioisotope therapy (except for benign thyroid disease)
  • Poor venous access and will be unable to receive study drug into a peripheral venous catheter.
  • Significant traumatic injury within 6 weeks prior to enrollment
  • Extradural tumor in contact with the spinal cord or tumor located where swelling in response to therapy may impinge upon the spinal cord
  • Serious or non-healing wound, ulcer, or bone fracture
  • Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry
  • History of myocardial infarction, ventricular arrhythmia, stable/unstable angina, symptomatic congestive heart failure, coronary/peripheral artery bypass graft or stenting or other significant cardiac disease within 6 months prior to study entry
  • QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥480 ms.
  • Any condition requiring the use of immunosuppression, excluding rheumatologic conditions treated with stable doses of corticosteroids (equivalent to £ prednisone 10 mg daily)
  • Ongoing hemodialysis or peritoneal dialysis
  • Poorly controlled severe Chronic Obstructive Pulmonary Disease (COPD)
  • Uncontrolled hypothyroidism or hyperthyroidism
  • Any medical condition that predisposes the subject to uncontrolled bleeding such as hemophilia, factor deficiencies, severe liver disease, or von Willebrand disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04105543

Layout table for location contacts
Contact: Cancer Connect 800-622-8922

Layout table for location information
United States, Wisconsin
University of Wisconsin Carbone Cancer Center Recruiting
Madison, Wisconsin, United States, 53792
Contact: Cancer Connect    800-622-8922   
Principal Investigator: Justine Bruce, MD         
Sponsors and Collaborators
University of Wisconsin, Madison
National Institute of Dental and Craniofacial Research (NIDCR)
Cellectar Biosciences, Inc.
Layout table for investigator information
Principal Investigator: Justine Bruce, MD University of Wisconsin, Madison
Additional Information:
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison Identifier: NCT04105543    
Other Study ID Numbers: UW19041
P50DE026787 ( U.S. NIH Grant/Contract )
2019-0681 ( Other Identifier: Institutional Review Board )
17-030-E ( Other Identifier: NIDCR Protocol Number )
A534260 ( Other Identifier: University of Wisconsin - Madison )
SMPH/MEDICINE/HEM-ONC ( Other Identifier: University of Wisconsin - Madison )
NCI-2019-05419 ( Registry Identifier: NCI Trial ID )
Protocol Version 7/7/2020 ( Other Identifier: UW Madison )
First Posted: September 26, 2019    Key Record Dates
Last Update Posted: July 28, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site